Acute Bronchiolitis. Acute bronchiolitis
Conditions
Interventions
Intervention 1: This study included children who received nebulization with magnesium sulfate, Ventolin, and 3% hypertonic saline. Treatment details in the intervention group: 50% magnesium sulfate at
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Days to 6 Months
Inclusion criteria
Inclusion criteria: Infants one to six months old Patients with mild to moderate respiratory status. Patients with a score of less than 9 on the Respiratory Distress Assessment Instrument (RDAI). Patients who have a first episode of respiratory distress with wheezing, based on the standard definition of bronchiolitis.
Exclusion criteria
Exclusion criteria: Respiratory rate greater than 100 per minute Heart rate greater than 180 per minute History of more than two episodes of respiratory distress in the past Presence of chronic heart and lung disease Syndromic face Metabolic or neurological disease History of prematurity (birth age less than 34 weeks) or use of mechanical ventilation in the neonatal period Positive family history of asthma Critically ill children who require immediate hospitalization due to dehydration, decreased level of consciousness, lethargy, or signs of respiratory failure Immunodeficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SpO2. Timepoint: The measurement time points in this study are as follows:One hour after each medication: Initial assessment of symptoms and changes after each treatment session.Daily for up to 3 days: Measurement and recording of data at specific time points during the 3 days of treatment (to continuously assess improvement and changes in symptoms).These time points are carefully adjusted to assess the effects of the treatment and changes in the patient's condition. Method of measurement: Measurement using a pulse oximeter at each assessment, especially one hour after taking the medication, and then daily.;Number of breaths. Timepoint: The measurement time points in this study are as follows:One hour after each medication: Initial assessment of symptoms and changes after each treatment session.Daily for up to 3 days: Measurement and recording of data at specific time points during the 3 days of treatment (to continuously assess improvement and changes in symptoms).These time points are carefully adjusted to assess the effects of the treatment and changes in the patient's condition. Method of measurement: Checking normal breathing by a doctor.;Heart rate. Timepoint: The measurement time points in this study are as follows:One hour after each medication: Initial assessment of symptoms and changes after each treatment session.Daily for up to 3 days: Measurement and recording of data at specific time points during the 3 days of treatment (to continuously assess improvement and changes in symptoms).These time points are carefully adjusted to assess the effects of the treatment and changes in the patient's condition. Method of measurement: Checking the pulse rate based on the location of the pulse. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of the disease. Timepoint: The measurement time points in this study are as follows:One hour after each medication: Initial assessment of symptoms and changes after each treatment session.Daily for up to 3 days: Measurement and recording of data at specific time points during the 3 days of treatment (to continuously assess improvement and changes in symptoms).These time points are carefully adjusted to assess the effects of the treatment and changes in the patient's condition. Method of measurement: Based on various criteria including RDAI.;Length of patient stay. Timepoint: Based on the time of admission for hospitalization and discharge of the patient. Method of measurement: Recording and calculating patient hospitalization and discharge time. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFahimeh Dehghani Mohammad Abadi
Iran University of Medical Sciences
Outcome results
None listed